Trial · NCT07880795
Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring
NCT07880795, Not yet recruiting, Emory University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring. Trials, record NCT07880795. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880795
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring
- NCT number
- NCT07880795
- Status
- Not yet recruiting
- Enrollment
- 180 participants, estimated
- Lead sponsor
- Emory University
- Conditions
- End Stage Kidney Disease (ESKD), Hyperglycaemia, Diabetes
- Interventions
- Continuous Glucose Monitoring (CGM)
- First posted
- 2026-10-19
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Prevalence of DM based on OGTT | Baseline through the end of the study (up to 15 days) | Proportion of participants meeting diagnostic criteria for diabetes mellitus based on fasting plasma glucose ≥126 mg/dL and/or 2-hour plasma glucose ≥200 mg/dL following a 75-g oral glucose tolerance test (OGTT). |
| Secondary | Hyperglycemic Events Detected by CGM | Baseline through the end of study (up to 15 study) | Number of hyperglycemic episodes detected by continuous glucose monitoring (CGM) per participant during the monitoring period. |
| Secondary | Hypoglycemic Events Detected by CGM | Baseline through the end of study (up to 15 study) | Number of hypoglycemic episodes detected by CGM per participant during the monitoring period. |
| Secondary | Average Daily Glucose | Baseline through the end of the study (up to 15 days) | Mean daily glucose concentration measured by CGM during the monitoring period, expressed in mg/dL and compared between participants with and without diabetes mellitus based on OGTT classification. |
| Secondary | Time in Range (70-140 mg/dL) | Baseline through the end of the study (up to 15 days) | Percentage of valid CGM readings between 70 and 140 mg/dL during the monitoring period, compared between participants with and without diabetes mellitus based on OGTT classification. |
| Secondary | Time in Range (70-180 mg/dL) | Baseline through the end of the study (up to 15 days) | Percentage of valid CGM readings between 70 and 180 mg/dL during the monitoring period, compared between participants with and without diabetes mellitus based on OGTT classification. |
| Secondary | Time Above Range (>140 mg/dL) | Baseline through the end of the study (up to 15 days) | Percentage of valid CGM readings exceeding 140 mg/dL during the monitoring period, compared between participants with and without diabetes mellitus based on OGTT classification. |
| Secondary | Time Above Range (>180 mg/dL) | Baseline through the end of the study (up to 15 days) | Percentage of valid CGM readings exceeding 180 mg/dL during the monitoring period, compared between participants with and without diabetes mellitus based on OGTT classification. |
| Secondary | Time Above Range (>250 mg/dL) | Baseline through the end of the study (up to 15 days) | Percentage of valid CGM readings exceeding 180 mg/dL during the monitoring period, compared between participants with and without diabetes mellitus based on OGTT classification. |
| Secondary | Mean Amplitude of Glycemic Excursions (MAGE) | Baseline through the end of the study (up to 15 days) | Mean amplitude of glycemic fluctuations calculated from CGM measurements during the monitoring period, expressed in mg/dL and compared between participants with and without diabetes mellitus based on OGTT classification. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880795
GET https://conductscience.org/api/trials/v1/NCT07880795/registered